Last reviewed · How we verify
mOPV2 at 6 and 8 weeks of age
mOPV2 at 6 and 8 weeks of age is a Live attenuated vaccine Biologic drug developed by Centers for Disease Control and Prevention. It is currently FDA-approved for Prevention of poliomyelitis caused by poliovirus type 2 in infants at 6 and 8 weeks of age.
mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.
mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection. Used for Prevention of poliomyelitis caused by poliovirus type 2 in infants at 6 and 8 weeks of age.
At a glance
| Generic name | mOPV2 at 6 and 8 weeks of age |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Live attenuated vaccine |
| Target | Poliovirus type 2 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
mOPV2 (monovalent oral polio vaccine type 2) contains a weakened live poliovirus type 2 that replicates in the intestinal tract, triggering both mucosal and systemic immune responses. This generates antibodies and cellular immunity against poliovirus type 2, providing protection against infection and disease. The vaccine is administered orally and has been used in global polio eradication campaigns.
Approved indications
- Prevention of poliomyelitis caused by poliovirus type 2 in infants at 6 and 8 weeks of age
Common side effects
- Vaccine virus shedding in stool
- Mild gastrointestinal symptoms
- Fever
- Vaccine-derived poliovirus (VDPV) in rare cases
Key clinical trials
- Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine (PHASE4)
- Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mOPV2 at 6 and 8 weeks of age CI brief — competitive landscape report
- mOPV2 at 6 and 8 weeks of age updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about mOPV2 at 6 and 8 weeks of age
What is mOPV2 at 6 and 8 weeks of age?
How does mOPV2 at 6 and 8 weeks of age work?
What is mOPV2 at 6 and 8 weeks of age used for?
Who makes mOPV2 at 6 and 8 weeks of age?
What drug class is mOPV2 at 6 and 8 weeks of age in?
What development phase is mOPV2 at 6 and 8 weeks of age in?
What are the side effects of mOPV2 at 6 and 8 weeks of age?
What does mOPV2 at 6 and 8 weeks of age target?
Related
- Drug class: All Live attenuated vaccine drugs
- Target: All drugs targeting Poliovirus type 2
- Manufacturer: Centers for Disease Control and Prevention — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of poliomyelitis caused by poliovirus type 2 in infants at 6 and 8 weeks of age
- Compare: mOPV2 at 6 and 8 weeks of age vs similar drugs
- Pricing: mOPV2 at 6 and 8 weeks of age cost, discount & access